The TD-4239 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood samples from the finger. It is intended to be used by a single person and should not be shared. The TD-4239 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus or be used on neonates. The TD-4239 Blood Glucose Test Strips are for use with the TD-4239 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples.

The TD-4239 Multi Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary, venous and neonatal whole blood samples. The TD-4239 Multi Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple patient use in professional healthcare settings as an aid in monitoring the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus. Professionals may test with capillary, venous and neonatal whole blood. Capillary samples may be drawn from the fingertip, and in the case of neonates, from the heel. The system is only used with single-use, auto-disabling lancing devices. The TD-4239 Multi Blood Glucose Test Strips are for use with the TD-4239 Multi Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary, venous and neonatal whole blood samples.

Device Description

The TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System consist of three main products: the meter, test strips and control solutions. These products have been designed, tested, and proven to work together as a system to produce accurate blood glucose test results. Use only TD-4239 and TD-4239 Multi test strips for the TD-4239 and TD-4239 Multi Blood Glucose Monitoring Systems, and use with the control solutions that has been tested and validated with this system to perform quality checks. The blood glucose detection method and measurement is by an electrochemical biosensor technology using FAD-dependent glucose dehydrogenase (FAD-GDH). The two blood glucose systems have the same technical components (same meter and test strips) and therefore the same performance data.

AI/ML Overview

Acceptance Criteria and Device Performance for TD-4239 Blood Glucose Monitoring System

This report summarizes the acceptance criteria and performance of the TD-4239 Blood Glucose Monitoring System, based on the provided 510(k) summary.

Note: The provided document is a 510(k) summary, which typically provides a high-level overview of performance studies rather than detailed raw data or exhaustive statistical analysis. Therefore, some information requested might not be explicitly stated or may require interpretation from the given context.

1. Table of Acceptance Criteria and Reported Device Performance

The 510(k) summary states that "Accuracy study and software validation were performed to evaluate the meter performance" and that "Results show that both devices are substantially equivalent to the predicate device K094005." This implies that the acceptance criteria are based on demonstrating equivalence to the predicate device's established accuracy and performance.

While specific numerical acceptance criteria (e.g., % within ±15 mg/dL or ±15%) are not explicitly listed in the provided text, blood glucose monitoring systems typically adhere to ISO 15197 standards or equivalent FDA-recognized guidance documents. The claim of "satisfactory performance" and "substantial equivalence" suggests that these industry-standard accuracy criteria were met.

For the purpose of this response, we infer the acceptance criteria based on standard expectations for blood glucose meters seeking FDA clearance.

Acceptance Criteria (Inferred from industry standards and claim of substantial equivalence)	Reported Device Performance (Summary statement)
Accuracy (Typically ISO 15197 related): A high percentage of results (e.g., ≥95%) within a specified range compared to a laboratory reference method. For example: - Within ±15 mg/dL for blood glucose < 100 mg/dL - Within ±15% for blood glucose ≥ 100 mg/dL	"Accuracy study and software validation were performed to evaluate the meter performance. Results show that both devices are substantially equivalent to the predicate device K094005." "The laboratory and clinical studies for the system performance... demonstrate the meter and test strip works well as a system." "Software verification and validation tests confirmed that the performance, safety and effectiveness... are equivalent to the predicate device."
Precision (Repeatability/Reproducibility): Low variability in results when the same sample is tested multiple times.	Not explicitly detailed in the provided text, but implied by "works well as a system" and "satisfactory performance."
Linearity: Ability to provide accurate results across the entire measuring range.	Not explicitly detailed, but implied by comprehensive "accuracy study."
Interfering Substances: Performance unaffected by common interfering substances.	Not explicitly detailed, but usually part of a comprehensive "accuracy study."
Usability/Human Factors: Ease of use and clear instructions.	Not explicitly detailed, but implied by "works well as a system."

Note on Inferring Acceptance Criteria: The absence of specific numerical criteria in the 510(k) summary is common for devices claiming substantial equivalence to a predicate. The FDA's review process would ascertain if adequate data demonstrating equivalence to the predicate (which would have met specific performance criteria) was provided.

2. Sample Size Used for the Test Set and Data Provenance

Test Set Sample Size: The document does not explicitly state the sample size used for the "accuracy study" or "clinical studies." It mentions "laboratory and clinical studies," suggesting a combination of controlled lab testing and potentially human subject testing.
Data Provenance (Country of Origin of the Data, Retrospective or Prospective): This information is not specified in the provided text. The submitter is TaiDoc Technology Corporation from Taiwan, so it is plausible that some or all studies were conducted in Taiwan or by a contracted laboratory. The summary does not indicate if the studies were retrospective or prospective. Given it's a 510(k) for a new device, prospective studies are typically performed for performance evaluation.

3. Number of Experts Used to Establish Ground Truth and Qualifications

The document does not mention the number of experts or their qualifications used to establish ground truth for the test set.

4. Adjudication Method for the Test Set

The document does not describe any specific adjudication method (e.g., 2+1, 3+1, none) for the test set. For blood glucose meters, the ground truth is typically established using a highly accurate laboratory reference method (e.g., YSI analyzer) rather than expert consensus on diagnostic imaging or clinical findings.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

A Multi-Reader Multi-Case (MRMC) comparative effectiveness study is not applicable to this device. Blood glucose monitoring systems are designed for direct quantitative measurement, not for human interpretation of complex medical cases or images that would typically involve multiple readers. Therefore, there is no discussion of human readers improving with or without AI assistance.

6. Standalone (Algorithm Only Without Human-in-the-Loop Performance)

Yes, the performance studies described are inherently standalone for the device. The TD-4239 Blood Glucose Monitoring System is an in vitro diagnostic device that quantitatively measures glucose. Its performance is evaluated based on the accuracy of its measurements compared to a reference method, without human interpretation of results as part of the core performance evaluation (though the user interprets the final numerical value). The "accuracy study" and "software validation" directly assess the algorithm's (and integrated system's) ability to produce accurate readings.

7. Type of Ground Truth Used

The type of ground truth used for blood glucose monitoring systems is typically a highly accurate laboratory reference method. While not explicitly named, this would commonly be a YSI glucose analyzer or another equivalent laboratory method. The "accuracy study" would compare the device's readings against these reference method readings.

8. Sample Size for the Training Set

The document does not explicitly mention a "training set" or its sample size. This is common for this type of device submission. While the device certainly relies on algorithms and potentially machine learning elements (e.g., for calibration, temperature compensation given the electrochemical biosensor), the "training" data used for developing these algorithms is usually internal to the manufacturer's development process and not typically detailed in this section of a 510(k) summary. The summary focuses on the validation of the finalized device.

9. How the Ground Truth for the Training Set Was Established

As the document does not explicitly refer to a "training set" in the context of the submission, it also does not describe how ground truth for such a set was established. However, if such a set were used during device development, the ground truth would similarly be established through comparison to a highly accurate laboratory reference method for glucose.

Summary

{0}------------------------------------------------

101635

AUG 3 1 2011

510 (k) Summary

Submitter Information Company name Contact person Address

Phone FAX E-mail Date Prepared

Name of Device Trade/Proprietary Name

Common Names Product Code Classification Panel Regulations

Predicate Device Trade/Proprietary Name:

Common/Usual Name: Submitter 510 (k) Number

TaiDoc Technology Corporation Teling Hsu 3F, 5F, No. 127, Wugong 2nd Rd., Wugu Township, Taipei County, 24888, Taiwan (+886-2) 6625-8188 ext.1176 (+886-2) 6625-0288 teling.hsu@taidoc.com.tw June 7th, 2010

TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System Blood glucose test system nbw, LFR Clinical Chemistry (75) Class II 21 CFR 862.1345

FORA G31 Blood Glucose Monitoring System (Model TD-4256) Blood qlucose test system TaiDoc Technology Corporation K094005

{1}------------------------------------------------

4. Device Description

The blood glucose detection method and measurement is by an electrochemical biosensor technology using FAD-dependent glucose dehydrogenase (FAD-GDH).

The two blood glucose systems have the same technical components (same meter and test strips) and therefore the same performance data.

5. Intended Use

For single use device

The TD-4239 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus or be used on neonates.

The TD-4239 Blood Glucose Test Strips are for use with the TD-4239 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples.

For multiple patient use device

{2}------------------------------------------------

Professionals may test with capillary, venous and neonatal whole blood. Capillary samples may be drawn from the fingertip, and in the case of neonates, from the heel.

The system is only used with single-use, auto-disabling lancing devices.

The TD-4239 Multi Blood Glucose Test Strips are for use with the TD-4239 Multi Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary, venous and neonatal whole blood samples.

6. Comparison to Predicate Device

The TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System have the same operating principle and same fundamental scientific technology as FORA G31 Blood Glucose Monitoring System (K094005). Modifications include test strip change, meter outer casing design, and software modifications. Accuracy study and software validation were performed to evaluate the meter performance. Results show that both devices are substantially equivalent to the predicate device K094005.

7. Performance Studies

The laboratory and clinical studies for the system performance of TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System demonstrate the meter and test strip works well as a system.

Software verification and validation tests confirmed that the performance, safety and effectiveness of the TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System are equivalent to the predicate device.

8. Conclusion

The TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System demonstrate satisfactory performance. The TD-4239 Blood Glucose Monitoring System and TD-4239 Multi Blood Glucose Monitoring System are therefore substantially equivalent to the predicate device.

{3}------------------------------------------------

Public Health Service

Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle is positioned to the right of a circular text element. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" and is arranged around the circumference of the circle.

Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993

Image /page/3/Picture/4 description: The image shows a date, "AUG 3 1 2011", in bold, sans-serif font. The letters and numbers are closely spaced together. The date appears to be stamped or printed, as the ink is slightly uneven.

Taidoc Technology Corporation c/o Teling Hsu 3f,5f, No.127 Wugong 2nd Rd, Wugu Township Taipei County Taiwan 24888

K101635 Re: TD-4239 Blood Glucose Monitoring System Trade name: I D-4239 Blood Glacose Monitoring System 21CFR §862.1345 Regulation Number: Glucose test system Regulation Name: Class II Regulatory Class: NBW, LFR Product Codes: Dated: August 25, 2011 Received: August 29, 2011

Dear Ms. Hsu,

We have reviewed your Section 510(k) premarket notification of intent to market the We have reviewed your Section > IU(K) prematics is substantially equivalent (for
device referenced above and have determined the levice is substanticate devices device referenced above and have determined the covles marketed predicate devices
the indications for use stated in the enclosure) to legally marketed predicate of the the indications for use stated in the enclosures to rogans, the enactment date of the enactment date of the marketed in interstate commerce problem that have been reclassified in accordance
Medical Device Amendments, or to devices that have been reclassified in accordance Medical Device Amendments, or to devices mar necessary that do not require
with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) the with the provisions of the Federal Pood, Drug, and Cosmons (Cherefore, market the the
approval of a premarket approval application (PMA). You may, the enerals approval of a premarket approval approvisions of the Act. The general controls
device, subject to the general controls provisions of the Act. The general controls device, subject to the general controls for annual registration, listing of devices,
provisions of the Act include requirements for annual registrating and provisions of the Act include requirements for annual regent and provided in
good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

lf your device is classified (see above) into either class II (Special Controls) or class III
n and the success of the blitional controls. Existing major regulations If your device is classitied (see above) into enner olso regulations)
(PMA), it may be subject to such additional controls. Existing major regulations (CFF (PMA), it may be subject to such additional controls. Existing major elegal and Crising your devices (CFR), Parts
affecting your device De tound in Title 21, Code of Federal affecting your device can be found in Title 21, Code of Pearline announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does
and the contract and and tempiration that your device complies with other Please be advised that FDA's issuance of a substantial oqur device complies with other
not mean that FDA has made a detectations administered by other not mean that FDA has made a determination that your dories administered by other requirements of the Act of any Federal statules and regulirements, including, but not
Federal agencies. You must comply with all the Act's requirements, including (21 CFR Pa Federal agencies. You must comply with an the rice is not in the Parts 801 and limited to: registration and listing (21 CPK Fall of medical device-related adverse events) (21
809); medical device reporting (reporting of medical device-related adverse ev 809); medical device reporting (reporting of medical as not of the requirements as set forth in the quality
CFR 803); and good manufacturing practice requirements as set fort CFR 603), and Bookstion (21 CFR Part 820).

{4}------------------------------------------------

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Viro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevicesforYou/Industry/default.htm.

Sincerely yours,

signature

Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

{5}------------------------------------------------

Attachment C4

Indications for Use

510(k) Number: K101635

Device Name: TD-4239 Blood Glucose Monitoring System

Indications for Use:

The TD-4239 Blood Glucose Test Strips are for use with the TD-4239 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples.

AND/OR

Prescription Use _ _ _ _ _ (21 CFR Part 801 Subpart D)

Over the Counter Use X (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Signature

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety KI 0163 510(k) =

Page 1 of 2

{6}------------------------------------------------

Indications for Use

510(k) Number: K101635

Device Name: TD-4239 Multi Blood Glucose Monitoring System

Indications for Use:

Professionals may test with capillary, venous and neonatal whole blood. Capillary samples may be drawn from the fingertip, and in the case of neonates, from the heel.

The system is only used with single-use, auto-disabling lancing devices.

Prescription Use _ X (21 CFR Part 801 Subpart D) AND/OR

Over the Counter Use _ X (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k)_ j< 10/ 63 ]

Page 2 of 2

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.